Molecular structure of Risedronic acid, CAS Number: 105462-24-6
Risedronic acid (CAS 105462-24-6)
See product citations (2)
Alternate Names:
RISEDRONATE
Application:
Risedronic acid is a potentially useful biophosphonate for bone resorption analysis
CAS Number:
105462-24-6
Purity:
≥98%
Molecular Weight:
283.11
Molecular Formula:
C7H11NO7P2
Supplemental Information:
This is classified as a Dangerous Good for transport and may be subject to additional shipping charges.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Risedronic acid is recognized in biochemical research for its significant role in influencing bone metabolism. Its action mechanism focuses on blocking osteoclast-mediated bone resorption, an essential part of bone renewal. By attaching to hydroxyapatite in bones, it interferes with the proton pump activity and the organization of the cytoskeleton in osteoclasts, which reduces their bone mineral dissolving capacity. Utilizing Risedronic acid enables researchers to uncover deeper insights into the equilibrium of bone formation and resorption, enhancing the understanding of skeletal integrity at a molecular level.
Risedronic acid (CAS 105462-24-6) References
- Risedronate for the prevention and treatment of corticosteroid-induced osteoporosis. | Dougherty, JA. 2002. Ann Pharmacother. 36: 512-6. PMID: 11895066
- Risedronate for the prevention of fractures in postmenopausal osteoporosis. | Sickels, JM. and Nip, CS. 2002. Ann Pharmacother. 36: 664-70. PMID: 11918518
- Alendronate and risedronate: what you need to know about their upper gastrointestinal tract toxicity. | Baker, DE. 2002. Rev Gastroenterol Disord. 2: 20-33. PMID: 12122976
- [VERT(Vertebral Efficacy with Risedronate Therapy)-MN(Multinational) Study and VERT-NA(North America) Study]. | Fukunaga, M. 2004. Nihon Rinsho. 62 Suppl 2: 433-6. PMID: 15035166
- Importance of calcium co-medication in bisphosphonate therapy of osteoporosis: an approach to improving correct intake and drug adherence. | Ringe, JD., et al. 2006. Drugs Aging. 23: 569-78. PMID: 16930085
- Review of the safety and efficacy of risedronate for the treatment of male osteoporosis. | Bobba, R. and Adachi, JD. 2007. Clin Interv Aging. 2: 275-82. PMID: 18044178
- [Evidence of risedronate for treatment of osteoporosis]. | Soen, S. 2007. Nihon Rinsho. 65 Suppl 9: 344-7. PMID: 18161128
- Effects of risedronate on osteoarthritis of the knee. | Iwamoto, J., et al. 2010. Yonsei Med J. 51: 164-70. PMID: 20191005
- Stimulation of in-vitro angiogenesis by low concentrations of risedronate is mitigated by 1,25-dihydroxyvitamin D3 or 24,25-dihydroxyvitamin D3. | Quesada-Gómez, JM., et al. 2015. J Steroid Biochem Mol Biol. 148: 214-8. PMID: 25445918
- Drug-repositioning screening identified fludarabine and risedronic acid as potential therapeutic compounds for malignant pleural mesothelioma. | Dell'Anno, I., et al. 2021. Invest New Drugs. 39: 644-657. PMID: 33300108
- Hydroxyapatite surface-functionalized monolithic column for selective in-tube solid phase microextraction of zoleronic acid and risedronic acid. | Wang, J., et al. 2021. J Chromatogr A. 1653: 462438. PMID: 34333172
- Identifying temporal patterns of adherence to antidepressants, bisphosphonates and statins, and associated patient factors. | Park, KH., et al. 2022. SSM Popul Health. 17: 100973. PMID: 35106359
- An open-label randomized study of the relative absorption of gastro-resistant risedronate taken fasted or with food versus immediate-release risedronate. | Kleinermans, D., et al. 2022. Pharmacol Res Perspect. 10: e00957. PMID: 35526121
- Design, Synthesis, Molecular Docking, Dynamics and in vitro Evaluation of Novel 2-substituted-1-hydroxyethane-1, 1-bis(phosphonic acid) Derivatives as Human Farnesyl Pyrophosphate Synthase Inhibitors with Expected Anticancer Activity. | Khedr, MA., et al. 2023. Curr Pharm Des. 29: 48-59. PMID: 36476435
Inhibitor of:
FDPS, and ICMT.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Risedronic acid, 100 mg | sc-203239 | 100 mg | $107.00 |